Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations

Press release – No. 7 / 2026   

Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations

Bringing significant experience from Vertex Pharmaceuticals and Shire

Copenhagen, Denmark and Boston, Massachusetts, April 14, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced the appointment of Eric Rojas, Vice President, Investor Relations, effective April 15, 2026. Eric will report to Henriette Wennicke, Chief Financial Officer, and will be based in Massachusetts, U.S.

Eric brings more than two decades of experience in investor relations and finance, having supported both US-listed and European-listed companies across biotech and pharma. He has held senior roles at several companies including Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK), and Shire who were acquired by Takeda for $62 billion. 

‘We are delighted to welcome Eric to Zealand Pharma. His deep knowledge of capital markets and strong network of relationships within the investment community will be invaluable as we execute our ambition to become a generational biotech and enter one of the most exciting and catalyst-rich periods in Zealand Pharma’s history,’ said Henriette Wennicke, Executive Vice President, Chief Financial Officer.

‘Zealand Pharma is at a compelling moment in its evolution. The pipeline is differentiated, the partnerships are strong and the data readouts ahead are significant. With the company also establishing its new research site in Cambridge, Massachusetts, it is a particularly exciting time to be joining. I look forward to working with the investment community to ensure Zealand Pharma’s story is as well understood as the science deserves,’ said Eric Rojas, Vice President, Investor Relations.

About Zealand Pharma  

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.  

To date, more than ten Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.